Advances in Radiotherapy for Glioblastoma and IDH-Mutant High-Grade Astrocytoma: A Biological and Mechanistic Perspective
Glioblastoma (GBM) and IDH-mutant high-grade astrocytoma remain therapeutically challenging. Historical GBM chemoradiation trials reported median overall survival of approximately 15–17 months; contemporary outcomes vary with molecular features, patient selection, and additional therapies. The 60 Gy in 30 fractions partial-brain regimen remains the reference standard for fit patients with newly diagnosed GBM. This narrative review examines radiotherapy based on its underlying biology, distinguishing GBM from IDH-mutant astrocytoma under the WHO molecular framework. It links DNA damage, cell-death programs, and radiation-induced immune signaling to the treatment response and DNA repair, stemness, hypoxia, and the microenvironment to resistance. These mechanisms motivate DNA-damage-response inhibitors, molecularly matched radiosensitizers, and immunotherapy combinations. Tumor treating fields are considered as an adjunctive non-ionizing modality. Proton therapy, FLASH, and MRI-guided adaptive radiotherapy are evaluated for their rationale and normal-tissue effects. Neurocognitive injury is discussed alongside the limitations of proposed hippocampal-sparing objectives. Personalization requires molecular selection and mechanism-matched treatment, with the clinical validation of benefits beyond dosimetry or imaging alone.
Authors
- Fatemeh Fekrmandi (ORCID: https://orcid.org/0000-0001-8412-9802)
- Arnab Chakravarti (ORCID: https://orcid.org/0000-0002-5392-8721)
Institutions
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- The Ohio State University (US)
Publication Details
- Journal
- Cancers
- Published
- 2026-11-19
- DOI
- https://doi.org/10.3390/cancers18223698
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00